NUVL

Nuvalent
NUVL

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$5.46B
EV
$4.34B
Shares Outstanding
76.55M
Beta
1.42

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$111.70
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Nuvalent, Inc.

gainify
NUVL

Nuvalent, Inc.

NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance,...

Sector

Healthcare

Industry

Biotechnology

CEO

Porter, James

Employees

142

IPO Date

2021-07-29

Headquarters

One Broadway, 14th Floor, Cambridge, Massachusetts, 02142, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved